Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
ASCO 2024 preview – jury still out on AbbVie's cancer push
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Lilly joins the folate receptor arena
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.
